GlassScriptPhysician profile
Joann Henwood
NPI 1689024523
$3,105.40
in general payments reported to CMS, 2019-2025
20 companies · $979 in 2025
The $979 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $100 · 2021: $555 · 2022: $631 · 2023: $480 · 2024: $242 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.03 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $701.19 | 2021-2025 | Cequa, Bromsite |
| Bausch & Lomb Americas INC. | $370.79 | 2022-2025 | Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $348.62 | 2024-2025 | Xdemvy |
| Abbvie INC. | $279.51 | 2022-2025 | |
| Sight Sciences, INC. | $180.05 | 2021-2025 | Tearcare System |
| Ivantis, INC | $167.56 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $162.38 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $150.18 | 2020-2024 | Acthar |
| Allergan, INC. | $136.92 | 2021 | |
| Dompe US, INC. | $100.91 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $96.61 | 2024-2025 | Tyrvaya |
| Alcon Vision LLC | $90.82 | 2022-2024 | Rocklatan, Simbrinza |
| Aerie Pharmaceuticals, INC. | $87.21 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $61.62 | 2021 | |
| Rxsight INC | $45.22 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $38.32 | 2022 | |
| Ani Pharmaceuticals, INC. | $37.27 | 2024-2025 | Iluvien, Purified Cortrophin Gel |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.22 | 2019 | |
| Amgen INC. | $13.92 | 2025 | Tepezza |
| Optos, INC. | $10.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Henwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.